Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin (XELOX) in Asian Patients with Colorectal Cancer: 4-Year Analysis

  • Chiu, Joanne (University Department of Medicine, The University of Hong Kong) ;
  • Tang, Vikki (University Department of Medicine, The University of Hong Kong) ;
  • Leung, Roland (University Department of Medicine, The University of Hong Kong) ;
  • Wong, Hilda (University Department of Medicine, The University of Hong Kong) ;
  • Chu, Kin Wah (Colorectal and Laparoscopic Surgery Center, The University of Hong Kong) ;
  • Poon, Jensen (University Department of Surgery, Queen Mary Hospital, The University of Hong Kong) ;
  • Epstein, Richard J. (Department of Oncology, St Vincent's Hospital, The Kinghorn Cancer Center) ;
  • Yau, Thomas (University Department of Medicine, The University of Hong Kong)
  • Published : 2013.11.30


Background: Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal. Moreover, uncertainties persist as to whether pharmacogenetic differences in Asian populations preclude equally tolerable and effective administration of these drugs. Method: One hundred consecutive patients with resected colorectal cancer received adjuvant XELOX (oxaliplatin 130 $mg/m^2$ on day 1 plus capecitabine 900 $mg/m^2$ twice daily on day 1 to 14 every 3 weeks for 8 cycles) at Queen Mary Hospital, Hong Kong. Endpoints monitored during follow-up were disease-free survival (DFS) and disease recurrence, overall survival (OS) and adverse events (AEs). Results: The median patient age was 56 years, 56% were diagnosed with rectal cancer and 44% with colonic cancer. After a median follow-up of 4.3 years (95% confidence interval, 3.2-4.7), 24 recurrences were confirmed including 13 patients who died due to progressive disease. Four-year DFS was 81% in colon cancer patients and 67% in rectal cancer patients (p=0.06 by log-rank test). For the cohort as a whole, OS was 90% at 3 years and 84% at 5 years. Treatment-related AEs led to early withdrawal in four patients. The commonest non-hematological AEs were neuropathy (91%), hand-foot syndrome (49%) and diarrhea (46%), while the commonest grade 3/4 AEs were neutropenia (11%) and diarrhea (10%). Conclusion: These results confirm the favourable long term survival benefit with good tolerability in using adjuvant XELOX in treating East Asian colorectal cancer patients.


Colorectal cancer;adjuvant chemotherapy;XELOX;capecitabine;5-fluorouracil


  1. Andre T, Boni C, Navarro M, et al (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27, 3109-16.
  2. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S (2002). Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest, 20, 333-9.
  3. de Gramont A, de Gramont A, Chibaudel B, et al (2011). The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer, 10, 218-26.
  4. Haller DG, Cassidy J, Clarke SJ, et al (2008). Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol, 26, 2118-23.
  5. Haller DG, Tabernero J, Maroun J, et al (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol, 29, 1465-71.
  6. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al (2001). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345, 638-46.
  7. Law CC, Fu YT, Chau KK, et al (2007). Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis Colon Rectum, 50, 2180-7.
  8. McCall JL, Cox MR, Wattchow DA (1995). Analysis of local recurrence rates after surgery alone for rectal cancer. Int J Colorectal Dis, 10, 126-32.
  9. McCollum AD, Catalano PJ, Haller DG, et al (2002). Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst, 94, 1160-7.
  10. O’Connell MJ, Martenson JA, Wieand HS, et al (1994). Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med, 331, 502-7.
  11. Raida M, Schwabe W, Hausler P, et al (2001). Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res, 7, 2832-9.
  12. Reddy GK (2004). Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial. Clin Colorectal Cancer, 4, 87-8.
  13. Sargent DJ, Patiyil S, Yothers G, et al (2007). End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol, 25, 4569-74.
  14. Schmoll HJ, Cartwright T, Tabernero J, et al (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol, 25, 102-9.
  15. Teitelbaum UR, Haller DG (2009). Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer. Nat Rev Clin Oncol, 6, 250-1.
  16. Tse VC, Ng WT, Lee V, et al (2011). Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. BMC Cancer, 11, 288.
  17. Wei X, Elizondo G, Sapone A, et al (1998). Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics, 51, 391-400.
  18. Yothers G, O’Connell MJ, Allegra CJ, et al (2011). Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol, 29, 3768-74.

Cited by

  1. Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study vol.15, pp.4, 2014,
  2. Colorectal Cancer Patient Characteristics, Treatment and Survival in Oman - a Single Center Study vol.16, pp.12, 2015,
  3. Types of Cancers Prevailing in Pakistan and their Management Evaluation vol.16, pp.9, 2015,
  4. Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a vol.8, pp.1663-9812, 2017,
  5. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer vol.80, pp.4, 2017,